CAS: 591-97-9; 1-Chloro-2-Butene

上下游产品

CAS号6117-91-5 巴豆醇 | CAS号598-32-3 3-丁烯-2-醇 | CAS号96233-06-6 but-3-en-2-yl d... | CAS号563-52-0 3-氯-1-丁烯 | CAS号4894-61-5 巴豆基氯,主要为反式 | CAS号7647-01-0 盐酸 | CAS号106-99-0 丁二烯 | CAS号64-19-7 冰醋酸 | CAS号7732-18-5 水 | CAS号106-98-9 正丁烯 | CAS号111712-50-6 2,3-dibromo-1-c... | CAS号18147-23-4 N-丁基甲基二氯化硅 | CAS号18409-00-2 1-ethoxybut-2-ene | CAS号639-58-7 三苯基氯化锡 | CAS号30056-32-7 Benzene,1-(2-bu... | CAS号598-32-3 3-丁烯-2-醇 | CAS号6117-91-5 巴豆醇 | CAS号53774-20-2 2-甲基-3-丁烯酸 | CAS号27829-70-5 ethyl (Z)-3-pen...

巴豆醇置于三苯基膦体系中,用 Various Solvent(S) 作为反应溶剂,化学反应 1.0H,以28%的收率获得产物1-氯-2-丁烯
参考文献:钌催化的烯炔环异构化和羟基环化与骨架重排
标题:钌催化的烯炔环异构化和羟基环化与骨架重排
摘要:发现中性的芳烃系的钌络合物是烯炔环异构化和羟基环化的催化剂前体.观测到的产物是骨骼重排过程的结果,并且包括不寻常的环化以形成六元环.对六元环产物的标记研究符合通过阳离子环丙基卡宾中间体进行的亲电活化机理.
DOI:10.1016/j.Jorganchem.2006.01.009

专利信息

专利号:US-4064150-A
优先权日:1976-05-26
标 题 :Synthesis of isoprenoid 1,5-dienes
发明人：KATZENELLENBOGEN JOHN A
权利人:UNIV ILLINOIS
摘要:Aliphatic acids containing an isoprenoid 1,5-diene moiety are prepared in high yields by the selective gamma alkylation of α,β-unsaturated acids with allylic electrophiles. The gamma-regioselectivity of the alkylation is controlled by the use of the dicopper(I) dienolates prepared from the α,β-unsaturated acids. The method offers a particularly facile means for synthesizing isoprenoid 1,5-diene natural products such as farnesoic acid by alkylation of senecioic acid with geranyl bromide; geranoic acid by alkylation of senecioic acid with 3,3-dimethallyl bromide; and dl-lanceol by alkylation of tiglic acid with an allylic bromide derived from dl-limonene. Such products find use in the synthesis of insect pheremones, insect juvenile hormones, and components of perfumes.

专利号:US-2010160670-A1
优先权日:2002-12-20
标 题 :Novel process for the preparation of chiral compounds derived from hexanoic acid esters and intermediates used in the synthesis of chiral-2-(bromomethyl)-2-ethylhexanoic acid
发明人：CROCQ-STUERGA VERONIQUE; ROUSSEL PATRICK
权利人:AVENTIS PHARMA SA
摘要:The present invention comprises a novel process for the preparation of a chiral compound of formula (I) n n n n n n n n n n wherein R 1 is hydroxyl or a group which activates the carboxyl and R 2 is alkyl optionally substituted by halogen or benzyl, its preparation, its application in the synthesis of chiral 2-bromomethyl-2-ethylhexanoic acid and novel intermediates.

专利号:US-2005240037-A1
优先权日:2002-07-23
标 题 :Method for the continuous intermediate separation of the solvent used in the oxirane synthesis with no coupling product
发明人：BASSLER PETER; GOBBEL HANS-GEORG; TELES JOAQUIN H; RUDOLF PETER
权利人:BASF AG
摘要:Process for the continuously operated distillation of the solvent used in the synthesis of an oxirane by reaction of a hydroperoxide with an organic compound, wherein the mixture comprising the solvent which is obtained in the synthesis and subsequent work-up is separated in a dividing wall column into a low-boiling fraction, an intermediate-boiling fraction and a high-boiling fraction and the solvent is taken off as intermediate-boiling fraction from the side offtake of the column.

专利号:US-6872727-B1
优先权日:1999-08-26
标 题:Polycyclic pyrimidine -2,4(1H,3H)-diones with functionalized alkyl residues at the 1- and/or 3-position(s); methods for their synthesis and pharmaceutical preparation
发明人：HERRMANN KONRAD; LEISTNER SIEGFRIED; WIPPICH PETRA
权利人:PRIVATES INST FUR BIOMEDIZINIS
摘要:Polycyclic pyrimidine-2,4(1H,3H)-diones with functionalized alkyl residues at the 1-, the 3-, or both position(s); methods for their synthesis, production, and pharmaceutical preparation. The invention concerns the synthesis of the above-described compounds, their chemical and structural characterization, and the analysis of their physiological/pharmacological activities in vitro and in vivo. These goals have been attained by the specification of routes of synthesis, methods for the production of the compounds, and the presentation of compound-specific characteristics. The substances encompassed by the present invention demonstrate pharmacologically significant collangenase/matrix metalloproteinase inhibitory activities. The specific example 1-(3-mercaptoprop-1-yl)-3-methyl-chinazolin-2,4(1H,3H)-dione will be presented in detail.

专利号:US-2024199658-A1
优先权日:2022-12-01
标 题:Direct synthesis of organotin alkoxides
发明人：JILEK ROBERT E; REED CHRISTOPHER J; NOVAS BRYAN
权利人:INPRIA CORP
摘要:Synthesis techniques are described for forming organotin trialkoxide compounds via direct alkylation of tin alkoxides. A first method involves reacting an alkali metal tin trialkoxide with an organohalide compound (RXn, where X is a halide atom and n≥1) to form a monoorgano tin trialkoxide represented by the formula R[Sn(OR′)3]n. The method can be used to form polytin trialkoxide compounds with a plurality of radiation sensitive C—Sn bonds. R and R′ include organo groups and can optionally comprise hetero-atoms and/or unsaturated bonds. A second method involves the ultraviolet light-driven reaction of a di-tin tetraalkoxide with an organohalide compound (RX) to form a monoorgano trialkoxide represented by the formula RSn(OR′)3. A third method involves the visible or ultraviolet light-driven reaction of a di-tin tetraalkoxide or an alkali metal tin trialkoxide with an fluorinated organohalide compound (RFX) to form a fluorinated monoorgano trialkoxide represented by the formula RFSn(OR′)3. The disclosed methods provide for high mono-organo specificity. Corresponding organotin trialkoxide compositions are also described. The compositions are useful for radiation patterning, especially with EUV radiation. The organotin trialkoxide compositions may be formed as radiation-patternable coatings on substrates.

专利号:US-2007015798-A1
优先权日:2005-02-25
标 题 :Efficient and stereoselective process for large scale synthesis of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-one derivatives
发明人：LI XUN; LEMAIRE SEBASTIEN; MARKO ISTVAN; WILLEMSENS ALBERT
权利人:LI XUN; LEMAIRE SEBASTIEN; MARKO ISTVAN; WILLEMSENS ALBERT
摘要:This invention relates to an efficient process for large scale stereoselective production of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-ones and key intermediates used for the preparation of benzofuranyl pyrroloquinolones as potent and selective PDE5 inhibitors for the treatment of erectile dysfunction, as well as pharmaceutical compositions and methods of treatment utilizing these compounds.